Financials in USD. Standardized financial statements.
A compact view of how Tengjun Biotechnology Corp. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $150.14M | $0 | $290 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $9.72M | $318,445 | $58 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $140.41M | -$318,445 | -$272,873 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +93.5% | 0.0% | -94094.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $124.35M | $419,789 | $666,677 | $39,493 | $29,898 | $32,486 | $36,823 | $64,892 | $103,094 | $20,450 |
| Operating Income? | $16.06M | -$738,234 | -$666,445 | -$39,493 | -$29,898 | -$32,486 | -$36,823 | -$64,892 | -$103,094 | -$20,450 |
| EBITDA? | $16.37M | -$424,109 | -$402,680 | $132,367 | -$29,898 | -$32,486 | -$46,823 | -$64,892 | -$103,094 | -$20,450 |
| Income Before Tax | $15.28M | -$747,525 | -$690,886 | -$59,865 | -$47,806 | -$48,231 | -$60,664 | -$74,709 | -$108,364 | -$21,314 |
| Income Tax Expense | $3.31M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1,000 | $0 |
| Net Income? | $11.35M | -$748,174 | -$690,886 | -$80,237 | -$47,806 | -$48,231 | -$60,664 | -$74,709 | -$108,364 | -$21,314 |
| EPS? | $0.14 | $-0.01 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $0.14 | $-0.01 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality